Clinical Trial Update: Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of preladenant for antipsychotic-induced movement disorders in schizophrenia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Akathisia
• Dyskinesia
• Schizophrenia

Drugs mentioned

• preladenant (preladenant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Akathisia, Drug-Induced, Dyskinesia, Drug-Induced | Phase 2 | Status: TERMINATED | Results posted: 2016-12-07